Astellas Pharma für 0 Euro bei ZERO ordern (zzgl. Spreads)

WKN DE: A0YGQP / ISIN: US04623U1025

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Astellas Pharma Inc Unsponsored American Deposit Receipt Repr 1-4 Sh

01.05.23		Astellas Enters into Definitive Agreement to Acquire Iveric Bio (PR Newswire)
29.04.23		XTANDI® (enzalutamide) plus Leuprolide Reduced the Risk of Metastasis by 58% in Non-Metastatic Hormone-Sensitive Prostate Cancer versus Placebo plus Leuprolide (PR Newswire)
15.04.23		Results from Astellas' Phase 3 SPOTLIGHT Trial of Investigational Zolbetuximab Published in The Lancet (PR Newswire)
12.04.23		CiRA, Kyoto University and Astellas Second Phase Joint Research Agreement Signed for Medical Applications of iPS Cells (PR Newswire)
04.04.23		Seagen: FDA Grants Accelerated Approval For Padcev Combination To Treat Metastatic Urothelial Cancer (RTTNews)
03.04.23		FDA Grants Accelerated Approval for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer (PR Newswire)
29.03.23		Astellas, Roche To Develop Integrated Diabetes Self-management Solution With BlueStar (RTTNews)
29.03.23		Astellas and Roche Diabetes Care Japan ink partnership agreement to develop and commercialize integrated diabetes self-management solution with BlueStar® (PR Newswire)
23.03.23		Pfizer And Astellas Say Phase 3 EMBARK Study Of XTANDI To Treat Prostate Cancer Meets Primary Goal (RTTNews)
21.03.23		Astellas Announces Positive Findings from Phase 3 GLOW Trial of Zolbetuximab during March ASCO Plenary Series (PR Newswire)
17.03.23		Phase 3 Study Shows XTANDI® (enzalutamide) plus Leuprolide Significantly Improves Metastasis-Free Survival in Men with Non-Metastatic Prostate Cancer (PR Newswire)
14.03.23		Astellas : Phase 3 Study Of Xtandi In Metastatic Hormone-sensitive Prostate Cancer Meets Main Goal (RTTNews)
14.03.23		Results from Astellas' Pivotal Phase 3 SKYLIGHT 1™ Study of Fezolinetant for Vasomotor Symptoms Due to Menopause Published in The Lancet (PR Newswire)
14.03.23		Astellas Announces Phase 3 China ARCHES Study of XTANDI® Meets Primary Endpoint (PR Newswire)
10.03.23		Astellas and Seagen Announce China's National Medical Products Administration Accepts Biologics License Application for Enfortumab Vedotin in Certain Patients with Locally Advanced or Metastatic U... (PR Newswire)
09.03.23		Astellas and BMT CTN Announce Topline Results from Phase 3 MORPHO Trial of Gilteritinib (PR Newswire)
22.02.23		Astellas Announces Update on Preliminary Safety and Efficacy Data from FORTIS Study of Investigational AT845 in Adults with Late-Onset Pompe Disease (PR Newswire)
20.02.23		Astellas Provides Update on Fezolinetant New Drug Application in U.S. (PR Newswire)
09.02.23		Astellas Commits to Achieve Net Zero Greenhouse Gas Emissions by 2050 (PR Newswire)
06.02.23		Astellas Pharma Board Approves Changes Of Management Structure (RTTNews)
06.02.23		Astellas Announces Change of President and CEO and Management Structure (PR Newswire)
24.01.23		Sandoz To Acquire Antifungal Agent Mycamine From Astellas Pharma (RTTNews)
24.01.23		Astellas Transfers MYCAMINE® Product Worldwide (PR Newswire)
20.01.23		Astellas Pharma : FDA Lifts Clinical Hold On Trial Of AT845 In Late-Onset Pompe Disease (RTTNews)
20.01.23		Astellas Announces Hold Lifted by FDA on FORTIS Clinical Trial of AT845 Investigational Treatment for Adult Patients with Late-Onset Pompe Disease (PR Newswire)
19.01.23		Astellas to Present Positive Findings from Phase 3 SPOTLIGHT Trial of Zolbetuximab during 2023 ASCO GI Cancers Symposium (PR Newswire)
19.01.23		Astellas Receives SBTi Approval for Revised Science-Based Climate Goals to Reduce Greenhouse Gas Emissions (PR Newswire)
09.01.23		Selecta Biosciences and Astellas Announce Exclusive Licensing and Development Agreement for Xork IgG Protease (PR Newswire)
22.12.22		Astellas, 3 Other Companies Collaborate To Reduce Environmental Burden In Field Of Pharma Packaging (RTTNews)
22.12.22		Astellas, Eisai, Daiichi Sankyo and Takeda Agree to Collaborate to Reduce Environmental Burden in the Field of Pharmaceutical Packaging (PR Newswire)
20.12.22		Astellas: PADCEV, KEYTRUDA Granted Priority Review In Treatment Of Metastatic Urothelial Cancer (RTTNews)
20.12.22		Astellas, Seagen and Merck Announce FDA Acceptance of Supplemental Biologics License Applications for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for the First-Line Treatment ... (PR Newswire)
16.12.22		Astellas Announces Positive Results From Phase 3 Trial Of Zolbetuximab Combination In Gastric Cancer (RTTNews)
16.12.22		Astellas Announces Zolbetuximab Meets Primary Endpoint in Phase 3 GLOW Trial as First-Line Treatment in Claudin 18.2 Positive, HER2-negative Locally Advanced Unresectable or Metastatic Gastric and... (PR Newswire)
14.12.22		Astellas and MBC BioLabs Announce 2022 Future Innovator Prize Awarded to Bespoke Biotherapeutics and Cellinfinity Bio (PR Newswire)
17.11.22		Astellas Announces Zolbetuximab Meets Primary Endpoint in Phase 3 SPOTLIGHT Trial as First-Line Treatment in Claudin 18.2 Positive, HER2-Negative Locally Advanced or Metastatic Gastric and Gastroe... (PR Newswire)
25.10.22		Astellas Pharma To Support Development Of Taysha's AAV-based Gene Therapy Programs (RTTNews)
25.10.22		Astellas and Taysha Gene Therapies Announce Strategic Investment to Support Development of Taysha's AAV-based Gene Therapy Programs (PR Newswire)
12.10.22		Astellas to Present Findings from Phase 3 Long-Term Safety Study of Fezolinetant in Oral Session at The North American Menopause Society 2022 Annual Meeting (PR Newswire)
04.10.22		Astellas and Pantherna Enter into a New Technology Evaluation Agreement for Research with Expanded Target Organ to Generate mRNA-Based Regenerative Medicine Programs Using Direct Reprogramming (PR Newswire)
30.09.22		Astellas : EMA Accepts Marketing Authorization Application For Fezolinetant (RTTNews)
30.09.22		European Medicines Agency Accepts Astellas' Marketing Authorization Application for Fezolinetant (PR Newswire)
20.09.22		Astellas and MBC BioLabs Announce Astellas Future Innovator Prize to Help Biotech Start-ups Accelerate Early Drug Discovery and Research Efforts (PR Newswire)
12.09.22		Seagen, Astellas, Merck: EV-103 Results Support Investigation Of Enfortumab Vedotin, Pembrolizumab (RTTNews)
12.09.22		Astellas, Seagen and Merck Announce Results of Clinical Trial Investigating PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) and PADCEV as Monotherapy in First-Line Advanced Urothe... (PR Newswire)
05.09.22		Astellas Announces Topline Results from Phase 3 Long-Term Safety Study of Fezolinetant in Mainland China (PR Newswire)
18.08.22		U.S. FDA Accepts Astellas' New Drug Application for Fezolinetant (PR Newswire)
02.08.22		Astellas Announces Management Structure (PR Newswire)
26.07.22		Astellas, Seagen Report Positive Topline Results For Padcev With Keytruda To Treat Urothelial Cancer (RTTNews)
26.07.22		Astellas and Seagen Announce Positive Topline Results For PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) as First-Line Treatment for Advanced Urothelial Cancer (PR Newswire)

Zurück | 1 | 2 | 3 | Weiter

Newssuche

Meistgelesene Nachrichten

Bitcoin-Halving bringt historische Enttäuschung: Schwächste Kursreaktion bisher

Valneva-Aktie dennoch fester: Valneva mit roten Zahlen

Novo Nordisk-Aktie trotzdem gesucht: Novo Nordisk dämpft Erwartungen für 2025

Nach Fed-Zinsentscheid: US-Börsen schließen mit Gewinnen -- ATX schließt höher -- DAX letztlich im Minus -- Asiatische Indizes beenden Handel überwiegend fester

AMD-Aktie mit Plus: AMD wächst kräftig

Solana Kurs Prognose: Ausbruch noch im Mai?

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2025 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	10.05.2025 03:13
Kaufwert:	EUR
	Hinzufügen Speichern

Astellas Pharma Aktie

WKN DE: A0YGQP / ISIN: US04623U1025

Nachrichten zu Astellas Pharma Inc Unsponsored American Deposit Receipt Repr 1-4 Sh

Newssuche

Meistgelesene Nachrichten